MacroGenics IncMacroGenics Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

This Sustainability rating for MacroGenics Inc indicates the company's transparency towards the United Nations Sustainable Development Goals. The webpage contains a zero-cost Sustainability analysis covering MacroGenics Inc. Browse to the bottom of the webpage for potential risks for MacroGenics Inc based on sector, geography and marketcap.

MacroGenics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.7; made up of an environmental score of 4.8, social score of 4.8 and governance score of 6.7.

SDG Transparency Score for MacroGenics Inc 
Low
0 - 3

5.7

Medium Impact
4 - 6
High
7 - 10
Last Score Update: 2023-07-01
What drives the score for MacroGenics Inc 
4.8

Environmental

4.8

Social

6.7

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
751Sigilon Therapeutics Inc
5.8
High
751Predilife SA
5.8
High
774MacroGenics Inc
5.7
High
774Adverum Biotechnologies Inc
5.7
High
774Dyadic International Inc
5.7
High
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does MacroGenics Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does MacroGenics Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does MacroGenics Inc report the average age of the workforce?

LockedSign up for free to unlock

Does MacroGenics Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does MacroGenics Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does MacroGenics Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does MacroGenics Inc offer flexible work?

LockedSign up for free to unlock

Does MacroGenics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does MacroGenics Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does MacroGenics Inc conduct supply chain audits?

LockedSign up for free to unlock

Does MacroGenics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does MacroGenics Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does MacroGenics Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does MacroGenics Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does MacroGenics Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does MacroGenics Inc disclose water use targets?

LockedSign up for free to unlock

Does MacroGenics Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did MacroGenics Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does MacroGenics Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does MacroGenics Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has MacroGenics Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does MacroGenics Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does MacroGenics Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does MacroGenics Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does MacroGenics Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does MacroGenics Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does MacroGenics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does MacroGenics Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is MacroGenics Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does MacroGenics Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does MacroGenics Inc disclose its waste policy?

LockedSign up for free to unlock

Does MacroGenics Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does MacroGenics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does MacroGenics Inc disclose energy use targets?

LockedSign up for free to unlock

Does MacroGenics Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does MacroGenics Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for MacroGenics Inc
These potential risks are based on the size, segment and geographies of the company.

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Sorry!

Failed to process!